SB11
Drug developer hits major milestone with Lucentis biosimilar
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from ...
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from ...